Stiftelsen WHO Collaborating Centre for International Drug Monitoring

Their core work

UMC (Uppsala Monitoring Centre) is the world's only WHO Collaborating Centre for International Drug Monitoring — the global custodian of VigiBase, the largest pharmacovigilance database on Earth, holding over 30 million adverse drug reaction reports from 130+ countries. Their core work is detecting and analyzing safety signals in medicines after they reach the market, turning raw ADR reports into actionable evidence for regulators, pharmaceutical companies, and healthcare systems. In EU research, they contribute as a specialized pharmacovigilance authority and a real-world health data asset: in WEB-RADR 2 they worked on digital reporting of adverse drug reactions, and in EHDEN they applied OMOP CDM data standardization to enable federated analysis of health records at European scale. Their unique position at the intersection of global drug safety governance and European health data infrastructure makes them an unusually credible node in any research consortium dealing with medicine safety, real-world evidence, or health data interoperability.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2018, so the dataset does not reveal a true temporal shift — but the two projects represent two distinct capability layers. WEB-RADR 2 (ending 2020) anchors UMC in their founding mission: operational pharmacovigilance and digital ADR reporting tools. EHDEN (running to 2024) marks a clear expansion into health data infrastructure — OMOP CDM standardization, OHDSI federation, FAIR principles, and machine learning on real-world evidence. The direction is from reactive safety surveillance (flagging problems after the fact) toward proactive, data-driven evidence generation at European scale.

UMC is moving from being a global pharmacovigilance custodian toward being a key node in European real-world evidence infrastructure, making them increasingly relevant for consortia combining drug safety with large-scale federated health data analysis.

How they like to work

UMC participates exclusively as a partner — they have not led a single H2020 project — which is consistent with their institutional model: they contribute world-class domain authority and data assets rather than managing project operations. Despite only two projects, they engaged 32 unique partners across 14 countries, indicating involvement in large, multi-stakeholder consortia (EHDEN alone involved dozens of European data partners). Collaborating with UMC means gaining access to their WHO mandate, global pharmacovigilance credibility, and VigiBase — assets that cannot be replicated by any other organization.

With 32 unique consortium partners across 14 countries from just two projects, UMC consistently operates inside large pan-European networks rather than bilateral arrangements. Their geographic spread reflects the European and global nature of both pharmacovigilance and health data standardization work.

What sets them apart

UMC is a genuinely singular institution — there is no other WHO Collaborating Centre for International Drug Monitoring anywhere in the world, and their access to VigiBase (the world's largest ADR database) is exclusive. For any consortium working on medicine safety, real-world evidence, or health data infrastructure, UMC brings regulatory legitimacy and a global data asset that cannot be substituted. Their position as a Swedish foundation with WHO mandate but deep EU research engagement also makes them a credible bridge between EU-funded science and WHO global health governance — rare in any H2020 consortium.

Highlights from their portfolio

• EHDEN
  The largest and longest of UMC's H2020 engagements (EUR 203,750, six years), EHDEN is the flagship European effort to standardize health data at scale using OMOP CDM and OHDSI tools — UMC's participation signals their strategic commitment to becoming a real-world evidence infrastructure partner, not just a pharmacovigilance watchdog.
• WEB-RADR 2
  Directly tied to UMC's WHO core mandate, this project extended mobile and web-based ADR reporting — representing UMC's contribution to modernizing the global drug safety reporting pipeline that feeds VigiBase.